PharmEasy
52W HIGH
Rs 9.08
52W LOW
Rs 6.16
1Y RETURN
+0.0%
About the Company
PharmEasy is an Indian digital healthcare platform operated by API Holdings that offers e-pharmacy, diagnostics, teleconsultation and health subscriptions. The platform connects consumers with licensed pharmacies and diagnostic labs, enabling medicine delivery, lab tests at home and electronic records. Corporate communications highlight partnerships with healthcare providers, quality checks, data security and programs aimed at affordability and adherence. PharmEasy has pursued growth through acquisitions and service expansion while emphasizing regulatory compliance and pharmacist-led order verification to support safe access to medicines and diagnostics across Indian cities.
Quick Facts
As of 7 Jul 2026
Quantity
Minimum investment Rs 1,00,000 (16,234 shares).
Settled in T+1 days. KYC verified dealers.
Get PharmEasy's live price
Share a few details and our desk sends you the latest price, availability and how to invest.
Trusted by 5,000+ investors · your details are never shared.
FUNDAMENTALS
Key Indicators
A snapshot of PharmEasy's valuation multiples and capital efficiency at a glance.
CURRENT SHARE PRICE
Rs 6.16
FACE VALUE / SHARE
Rs 1
BOOK VALUE / SHARE
Rs 1.92
PRICE TO EARNING (PE)
N/A
PRICE / BOOK
0.00
MARKET CAP
10.49K Cr
DEBT TO EQUITY
0.62
RETURN ON EQUITY
-48.05%
52 WEEK HIGH
Rs 9.08
52 WEEK LOW
Rs 6.16
FINANCIALS
Fundamentals & Financial Statements
Price / Share
₹5.6
P/B Ratio
0.00
Face Value
₹1
| Particulars | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 5,729 | 6,644 | 5,664 | 5,872 |
| Cost of Material Consumed | 5,342 | 5,669 | 4,737 | 4,918 |
| Change in Inventory | -229 | 62 | 143 | -4 |
| Gross Margins | 10.75% | 13.74% | 13.84% | 16.31% |
| Employee Benefit Expenses | 1,459 | 1,283 | 699 | 908 |
| Other Expenses | 1,502 | 1,051 | 731 | 711 |
| EBITDA | -2,345 | -1,421 | -646 | -661 |
| OPM | -40.93% | -21.39% | -11.41% | -11.26% |
| Other Income | -1,185 | -2,866 | 931 | -181 |
| Finance Cost | 258 | 666 | 728 | 506 |
| Depreciation & Amortisation | 159 | 243 | 216 | 169 |
| EBIT | -2,504 | -1,664 | -862 | -830 |
| EBIT Margins | -43.71% | -25.05% | -15.22% | -14.13% |
| Profit Before Tax | -3,977 | -5,196 | -2,522 | -1,517 |
| PBT Margins | -69.42% | -78.21% | -44.53% | -25.83% |
| Tax | 22 | 15 | 11 | 55 |
| Profit After Tax | -3,999 | -5,211 | -2,533 | -1,572 |
| Net Profit Margin | -69.8% | -78.43% | -44.72% | -26.77% |
| EPS | ₹-6.51 | ₹-8.48 | ₹-3.9 | ₹-2.26 |
PROCESS
How to Buy PharmEasy
Enquire
Share your requirement and preferred quantity with our desk.
Get a quote
Receive the latest indicative price, lot size and availability.
Complete KYC
Quick paperwork with a KYC-verified counterparty.
Receive shares
Shares credited to your demat, typically within T+1 days.
OWNERSHIP
Shareholding Pattern
Indicative ownership structure. Exact filed breakup confirmed at dealing.
CORPORATE CALENDAR
Events & Announcements
Typical annual calendar. Exact dates updated as the company announces them.
LEADERSHIP
Management Team
Standard governance structure. Named directors added as verified. Tap any role to see what they do and why it matters for investors.
REPORTS
Download Financial Results
Need the official filed reports?
Get audited annual & quarterly filings (MCA / RTA) for PharmEasy straight from our desk.
QUESTIONS
Frequently Asked Questions
NEWS & INSIGHTS
Latest on PharmEasy & its sector
CORPORATE
Company Details
ISIN
INE0DJ201029
CIN
U60100MH2019PLC323444
PAN
AASCA1201E
REGISTRAR (RTA)
Link Intime
DEPOSITORY
NSDL & CDSL
OUTSTANDING SHARES
17,03,24,95,304
REGISTERED OFFICE
Unit 301, B Wing, Kanakia Wall Street, Andheri (East), Mumbai, Maharashtra 400093, India
SECTOR
Health Care
INDUSTRY
E-Pharmacy & Healthtech
READY TO INVEST?
Enquire with Neoma Capital
Talk to a CA advisor about PharmEasy. Get pricing, availability, and transfer process guidance.
Disclaimer: Prices shown are indicative and for reference purposes only. Unlisted shares carry higher risk than listed equities. Past performance is not indicative of future results. Financial statements, where shown, are compiled from company filings (MCA / RTA) and may be restated in subsequent filings. Neoma Capital does not provide investment advice. Please consult a qualified financial advisor. Transactions subject to KYC verification and SEBI regulations.